Medtronic wins Canadian approval for brain-stim epilepsy therapy
Medtronic (NYSE:MDT) touted Health Canada approval for its deep brain stimulation therapy for refractory epilepsy patients. The DBS system delivers directed electrical impulses via an implanted device to a part of the brain involved in seizures.
Medtronic’s DBS won CE Mark approval for epileptic patients in the European Union in August 2010, but has yet to gain similar approval from the U.S. FDA.
The device is under humanitarian device exemption in the U.S. for a number of conditions, including treatment-resistant obsessive-compulsive disorder and advanced Parkinson’s disease. More than 85,000 patients worldwide have received Medtronic DBS therapy to date, according to a press release. Read more